Cerbios-Pharma showing new manufacturing capabilities at ChemOutsourcing 2019

news-releasesCERBIOS-PHARMA SA
July 24th 2019

Lugano, Switzerland: – Pharmaceutical ingredient specialist Cerbios-Pharma SA (Cerbios) will showcase its expanded high-potency active ingredient manufacturing capabilities at September’s ChemOutsourcing annual conference in New Jersey, USA.Cerbios has become an established presence at the ChemOutsourcing event and will be an exhibitor, with a stand at Booth 95 in the exhibition zone at the New Jersey Hilton of Parsippany.

Uprated HPAPI manufacturing

The Cerbios display will feature the company’s upgraded and expanded production facilities for HPAPIs, enabled by recent opening of a third manufacturing line at its Chemical Division Lugano facility.

The company will also contribute to the conference agenda, with a case study presentation by Chief Scientific Officer Dr. Claudio Pozzoli on ‘Quality and development by design for robust chemical process’, during the morning session on Day Two (September 18).

Selecting the right CMO partner

Further, Cerbios Business Development Manager Dr. Simone Sala will participate in the panel session on ‘Important Considerations for Virtual & Emerging Pharma in the Selection of a CMO Partner for High Potency Drug Substance & Drug Products’.

“We are looking forward to returning to ChemOutsourcing and the chance to exchange knowledge with its highly expert audience,” said Simone Sala.

“Once again we will be reaching out to CMC outsourcing managers, buyers, procurement and R&D professionals to discuss opportunities to take advantage of our end-to-end offers and forge long term partnerships,” said Dr. Sala.

About Cerbios-Pharma

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.

Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used in Oncology, as well as in the treatment Respiratory and Dermatological disorders.

Exclusive CDMO services are offered for the development and manufacturing of high potency active ingredients (HPAIs) as well as for biological products including monoclonal antibodies, recombinant proteins, antibody drug conjugates (ADCs) and pharma probiotics.

Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs, with paramount ability to supply all technical documentation and support necessary for successful registration. Cerbios’ commercial products are marketed worldwide, primarily in Europe, USA, Japan and India.

Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics of Denmark and with Germany’s Oncotec.

PROVEO can offer an ADCs end-to-end service from substance development through manufacturing to fill & finish.

About ChemOutsourcing 2019

ChemOutsourcing is the USA’s largest API and Pharmaceutical Ingredients show, focusing on the API development supply chain from raw materials through drug discovery, process and chemical development, to commercial manufacturing of branded and generic small molecule API’s and drug products.

ChemOutsourcing 2019, a three day event opening September 18 at the New Jersey Hilton in Parsippany, NJ, is expected to attract some 750 visitors, representing project and executive management and business development personnel from the pharmaceutical, biotech, chemical, and chemistry services industries from 30 countries.

A co-located exhibition will feature more than 130 companies and organizations.

The event is organized by ChemOutsourcing in association with Apaporis LLC. Further information at: http://www.chemoutsourcing.com/.

TRENDING ARTICLE

CERBIOS-PHARMA Company Brochure

FREE DOWNLOAD
Cerbios-Pharma showing new manufacturing capabilities at ChemOutsourcing 2019

Cerbios offers a range of advanced ADC manufacturing services, including ability to handle cytotoxic payloads